{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:15Z","timestamp":1789628475154,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["CSC 202308430051"],"award-info":[{"award-number":["CSC 202308430051"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["CSC 201906220218"],"award-info":[{"award-number":["CSC 201906220218"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bvth.2025.100100","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T22:14:00Z","timestamp":1754345640000},"page":"100100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa"],"prefix":"10.1016","volume":"2","author":[{"given":"Ischa M. S.","family":"Hoornstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmen","family":"Middelveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-5472","authenticated-orcid":false,"given":"Claudia","family":"Sch\u00f6nichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-5121","authenticated-orcid":false,"given":"Johan W. M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1251-6586","authenticated-orcid":false,"given":"Hendrik","family":"Stragier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"de Laat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-7068","authenticated-orcid":false,"given":"Mark","family":"Roest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bvth.2025.100100_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/HPC.0000000000000177","article-title":"Andexanet alfa (Andexxa) formulary review","volume":"18","author":"Beik","year":"2019","journal-title":"Crit Pathw Cardiol"},{"issue":"19","key":"10.1016\/j.bvth.2025.100100_bib2","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bvth.2025.100100_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JBM.S121550","article-title":"Reversing factor Xa inhibitors - clinical utility of andexanet alfa","volume":"8","author":"Kaatz","year":"2017","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.bvth.2025.100100_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12028-020-01161-5","article-title":"Andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitors in intracranial hemorrhage","volume":"35","author":"Ammar","year":"2021","journal-title":"Neurocrit Care"},{"issue":"1","key":"10.1016\/j.bvth.2025.100100_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.bvth.2025.100100_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"21","key":"10.1016\/j.bvth.2025.100100_bib7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bvth.2025.100100_bib8","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/jth.15697","article-title":"Regulation of coagulation by tissue factor pathway inhibitor: implications for hemophilia therapy","volume":"20","author":"Mast","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.bvth.2025.100100_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11239-018-1617-2","article-title":"Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy","volume":"45","author":"Sartori","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"16","key":"10.1016\/j.bvth.2025.100100_bib10","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2016003616","article-title":"Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors","volume":"2","author":"Kalathottukaren","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bvth.2025.100100_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241247558","article-title":"Andexanet alfa neutralizes the anticoagulant effects of unfractionated heparin of bovine, ovine and porcine origin almost as protamine sulfate","volume":"30","author":"Siddiqui","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.bvth.2025.100100_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1060028020943160","article-title":"Andexanet alfa, the possible alternative to protamine for reversal of unfractionated heparin","volume":"55","author":"Maneno","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.bvth.2025.100100_bib13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.annemergmed.2019.12.026","article-title":"Is it truly \u201calpha\u201d? Incidence of thrombotic events with andexanet alfa at a single academic medical center","volume":"75","author":"Parsels","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"4","key":"10.1016\/j.bvth.2025.100100_bib14","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300360RR","article-title":"Endothelial-mediated regulation of platelet activation: involvement of multiple protein kinases","volume":"38","author":"Provenzale","year":"2024","journal-title":"FASEB J"},{"issue":"6","key":"10.1016\/j.bvth.2025.100100_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1160\/TH15-10-0821","article-title":"Strenuous exercise induces a hyperreactive rebalanced haemostatic state that is more pronounced in men","volume":"115","author":"Huskens","year":"2016","journal-title":"Thromb Haemost"},{"issue":"21","key":"10.1016\/j.bvth.2025.100100_bib16","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1182\/bloodadvances.2023010027","article-title":"Crucial roles of red blood cells and platelets in whole blood thrombin generation","volume":"7","author":"Sun","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bvth.2025.100100_bib17","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1055\/s-0042-1757163","article-title":"Hyperresponsive platelets and a reduced platelet granule release capacity are associated with severity and mortality in COVID-19 patients","volume":"122","author":"Garishah","year":"2022","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.bvth.2025.100100_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12775","article-title":"In vitro reversal of direct factor Xa inhibitors: direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex\/Kcentra","volume":"6","author":"Brinkman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.bvth.2025.100100_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620983466","article-title":"Thrombin generation profile in various lymphoma sub-groups and its augmentation by andexanet alfa","volume":"26","author":"Siddiqui","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"10.1016\/j.bvth.2025.100100_bib20","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2017.174037","article-title":"Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma","volume":"102","author":"Ersayin","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.bvth.2025.100100_bib21","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1182\/blood.V126.23.4672.4672","article-title":"Plasma Tissue Factor Pathway Inhibitor (TFPI) levels in healthy subjects and patients with hemophilia A and B","volume":"126","author":"Gu","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bvth.2025.100100_bib22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jth.14627","article-title":"Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombin","volume":"18","author":"Ahnstr\u00f6m","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.bvth.2025.100100_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003553","article-title":"Thrombin generation and atherothrombosis: what does the evidence indicate?","volume":"5","author":"Ten Cate","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327225000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327225000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:28:29Z","timestamp":1764170909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327225000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950327225000579"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2025.100100","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2025.100100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100100"}}